OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $343.00 0.00 (0.00%) As of 09/17/2026 09:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsNews and TrendsSEC FilingsShort Interest About Genmab A/S Stock (OTCMKTS:GNMSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$343.00▼$343.0050-Day Range$274.50▼$343.0052-Week Range$232.34▼$352.00Volume209 shsAverage Volume3,066 shsMarket Capitalization$21.12 billionP/E Ratio26.90Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing antibody-based medicines for cancer and other serious diseases. Founded in 1999, the company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system and target disease-related cells. Genmab’s products include Darzalex (daratumumab), developed with Janssen Biotech for certain blood cancers; Epkinly (epcoritamab), developed with AbbVie for certain types of B-cell lymphoma; and Tivdak (tisotumab vedotin), developed with Seagen, now part of Pfizer, for recurrent or metastatic cervical cancer. Genmab also discovered the antibody underlying Kesimpta (ofatumumab), a Novartis treatment for multiple sclerosis. The company continues to advance a pipeline of proprietary and partnered antibody therapeutics. Genmab serves international markets through its own research and development operations and collaborations with global pharmaceutical companies. Its activities extend across North America, Europe and Asia, with corporate and research operations in Denmark and the United States as well as additional international locations. Jan van de Winkel, a co-founder of Genmab, has served as the company’s chief executive officer since 2010.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreGNMSF MarketRank™: Genmab A/S scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genmab A/S. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 26.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 26.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.33% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 23.95, which indicates bearish sentiment.Change versus previous monthShort interest in Genmab A/S has recently decreased by 0.99%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Genmab A/S this week, compared to 1 article on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsGenmab A/S has minimal institutional ownership at this time.Read more about Genmab A/S's insider trading history. Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNMSF Stock News HeadlinesGenmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Still a Buy?September 18 at 5:02 AM | americanbankingnews.comGenmab Updates Articles of Association, Preserves Broad Capital-Raising PowersSeptember 9, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 18 at 1:00 AM | Stansberry Research (Ad)Genmab Calls October Extraordinary General Meeting to Address Board Remuneration and Shareholder OutreachSeptember 8, 2026 | tipranks.comCould Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?August 26, 2026 | insidermonkey.comGenmab Updates Articles of Association, Expands Capital-Raising FlexibilityAugust 12, 2026 | tipranks.comGenmab Boosts Share Capital After Employee Warrant ExerciseAugust 11, 2026 | tipranks.comGenmab A/S (GMAB) Releases Q2 2026 Earnings: Revenue Up 24.9%, Net Income Falls 9.8%August 6, 2026 | quiverquant.comQSee More Headlines GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $314.00 at the start of the year. Since then, GNMSF shares have increased by 9.2% and is now trading at $343.00. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Tuesday, February, 17th. The company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $3.10 by $2.55. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a net margin of 19.08% and a trailing twelve-month return on equity of 14.89%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/17/2026Today9/18/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:GNMSF CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees3,029Year Founded1999Profitability EPS (Trailing Twelve Months)$12.75 Trailing P/E Ratio26.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$963 million Net Margins19.08% Pretax Margin21.93% Return on Equity14.89% Return on Assets7.73% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$3.72 billion Price / Sales5.68 Cash Flow$15.74 per share Price / Cash Flow21.79 Book Value$88.49 per share Price / Book3.88Miscellaneous Outstanding Shares61,570,000Free Float60,622,000Market Cap$21.12 billion OptionableNot Optionable Beta0.79 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:GNMSF) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
